Italian scientists pioneering a new gene transfer treatment for the blood disorder beta-thalassemia have successfully completed preclinical trials, claiming they can correct the lack of beta-globin in patients' blood cells which causes the disease. The research reveals how gene therapy may represent a safe alternative to current cures that are limited to a minority of patients.